Neoadjuvant systemic therapy in melanoma

recommendations of the International Neoadjuvant Melanoma Consortium

Rodabe N. Amaria, Alexander M. Menzies, Elizabeth M. Burton, Richard A. Scolyer, Michael T. Tetzlaff, Robert Antdbacka, Charlotte Ariyan, Roland Bassett, Brett Carter, Adil Daud, Mark Faries, Leslie A. Fecher, Keith T. Flaherty, Jeffrey E. Gershenwald, Omid Hamid, Angela Hong, John M. Kirkwood, Serigne Lo, Kim Margolin, Jane Messina & 64 others Michael A. Postow, Helen Rizos, Merrick I. Ross, Elisa A. Rozeman, Robyn P.M. Saw, Vernon Sondak, Ryan J. Sullivan, Janis M. Taube, John F. Thompson, Bart A. van de Wiel, Alexander M. Eggermont, Michael A. Davies, Miles C. Andrews, Donald A. Berry, Matthew S. Block, Genevieve M. Boland, Kathryn B. Bollin, Matteo S. Carlino, Richard D. Carvajal, Jonathan Cohen, Diwakar Davar, Keith A. Delman, Reinhard Dummer, Michael D. Farwell, David E. Fisher, Alberto Fusi, Isabella C. Glitza, Tanja D. de Gruijl, David E. Gyorki, Axel Hauschild, Tina J. Hieken, James Larkin, David H. Lawson, Celeste Lebbe, Jeffrey E. Lee, Michael C. Lowe, Jason J. Luke, Grant A. McArthur, David F. McDermott, Jennifer L. McQuade, Tara C. Mitchell, Teresa M. Petrella, Peter A. Prieto, Igor Puzanov, Caroline Robert, April K. Salama, Shaneen Sandhu, Dirk Schadendorf, Alexander N. Shoushtari, Jeffrey A. Sosman, Susan M. Swetter, Ken K. Tanabe, Samra Turajlic, Douglas Tyler, Scott E. Woodman, Frances C. Wright, Jonathan S. Zager, Paolo A. Ascierto, Andrew J. Spillane, Alexander C.J. van Akkooi, Jennifer A. Wargo, Christian U. Blank, Hussein A. Tawbi, Georgina V. Long

Research output: Contribution to journalReview article

Abstract

Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to treatment, highlighting a crucial need to identify biomarkers and understand mechanisms of response and toxicity. Neoadjuvant therapy for regional metastases might improve operability and clinical outcomes over upfront surgery and adjuvant therapy, and has become an established role for drug development and biomarker discovery in other cancers (including locally advanced breast cancer, head and neck squamous cell carcinomas, gastroesophageal cancer, and anal cancer). Patients with clinically detectable stage III melanoma are ideal candidates for neoadjuvant therapy, because they represent a high-risk patient population with poor outcomes when treated with upfront surgery alone. Neoadjuvant therapy is now an active area of research for melanoma with numerous completed and ongoing trials (since 2014) with disparate designs, endpoints, and analyses under investigation. We have, therefore, established the International Neoadjuvant Melanoma Consortium with experts in medical oncology, surgical oncology, pathology, radiation oncology, radiology, and translational research to develop recommendations for investigating neoadjuvant therapy in melanoma to align future trial designs and correlative analyses. Alignment and consistency of neoadjuvant trials will facilitate optimal data organisation for future regulatory review and strengthen translational research across the melanoma disease continuum.

Original languageEnglish (US)
Pages (from-to)e378-e389
JournalThe Lancet Oncology
Volume20
Issue number7
DOIs
StatePublished - Jul 1 2019
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
Melanoma
Translational Medical Research
Biomarkers
Anus Neoplasms
Surgical Pathology
Radiation Oncology
Medical Oncology
Head and Neck Neoplasms
Radiology
Neoplasms
Therapeutics
Breast Neoplasms
Neoplasm Metastasis
Survival
Research
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Oncology

Cite this

Amaria, R. N., Menzies, A. M., Burton, E. M., Scolyer, R. A., Tetzlaff, M. T., Antdbacka, R., ... Long, G. V. (2019). Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. The Lancet Oncology, 20(7), e378-e389. https://doi.org/10.1016/S1470-2045(19)30332-8

Neoadjuvant systemic therapy in melanoma : recommendations of the International Neoadjuvant Melanoma Consortium. / Amaria, Rodabe N.; Menzies, Alexander M.; Burton, Elizabeth M.; Scolyer, Richard A.; Tetzlaff, Michael T.; Antdbacka, Robert; Ariyan, Charlotte; Bassett, Roland; Carter, Brett; Daud, Adil; Faries, Mark; Fecher, Leslie A.; Flaherty, Keith T.; Gershenwald, Jeffrey E.; Hamid, Omid; Hong, Angela; Kirkwood, John M.; Lo, Serigne; Margolin, Kim; Messina, Jane; Postow, Michael A.; Rizos, Helen; Ross, Merrick I.; Rozeman, Elisa A.; Saw, Robyn P.M.; Sondak, Vernon; Sullivan, Ryan J.; Taube, Janis M.; Thompson, John F.; van de Wiel, Bart A.; Eggermont, Alexander M.; Davies, Michael A.; Andrews, Miles C.; Berry, Donald A.; Block, Matthew S.; Boland, Genevieve M.; Bollin, Kathryn B.; Carlino, Matteo S.; Carvajal, Richard D.; Cohen, Jonathan; Davar, Diwakar; Delman, Keith A.; Dummer, Reinhard; Farwell, Michael D.; Fisher, David E.; Fusi, Alberto; Glitza, Isabella C.; de Gruijl, Tanja D.; Gyorki, David E.; Hauschild, Axel; Hieken, Tina J.; Larkin, James; Lawson, David H.; Lebbe, Celeste; Lee, Jeffrey E.; Lowe, Michael C.; Luke, Jason J.; McArthur, Grant A.; McDermott, David F.; McQuade, Jennifer L.; Mitchell, Tara C.; Petrella, Teresa M.; Prieto, Peter A.; Puzanov, Igor; Robert, Caroline; Salama, April K.; Sandhu, Shaneen; Schadendorf, Dirk; Shoushtari, Alexander N.; Sosman, Jeffrey A.; Swetter, Susan M.; Tanabe, Ken K.; Turajlic, Samra; Tyler, Douglas; Woodman, Scott E.; Wright, Frances C.; Zager, Jonathan S.; Ascierto, Paolo A.; Spillane, Andrew J.; van Akkooi, Alexander C.J.; Wargo, Jennifer A.; Blank, Christian U.; Tawbi, Hussein A.; Long, Georgina V.

In: The Lancet Oncology, Vol. 20, No. 7, 01.07.2019, p. e378-e389.

Research output: Contribution to journalReview article

Amaria, RN, Menzies, AM, Burton, EM, Scolyer, RA, Tetzlaff, MT, Antdbacka, R, Ariyan, C, Bassett, R, Carter, B, Daud, A, Faries, M, Fecher, LA, Flaherty, KT, Gershenwald, JE, Hamid, O, Hong, A, Kirkwood, JM, Lo, S, Margolin, K, Messina, J, Postow, MA, Rizos, H, Ross, MI, Rozeman, EA, Saw, RPM, Sondak, V, Sullivan, RJ, Taube, JM, Thompson, JF, van de Wiel, BA, Eggermont, AM, Davies, MA, Andrews, MC, Berry, DA, Block, MS, Boland, GM, Bollin, KB, Carlino, MS, Carvajal, RD, Cohen, J, Davar, D, Delman, KA, Dummer, R, Farwell, MD, Fisher, DE, Fusi, A, Glitza, IC, de Gruijl, TD, Gyorki, DE, Hauschild, A, Hieken, TJ, Larkin, J, Lawson, DH, Lebbe, C, Lee, JE, Lowe, MC, Luke, JJ, McArthur, GA, McDermott, DF, McQuade, JL, Mitchell, TC, Petrella, TM, Prieto, PA, Puzanov, I, Robert, C, Salama, AK, Sandhu, S, Schadendorf, D, Shoushtari, AN, Sosman, JA, Swetter, SM, Tanabe, KK, Turajlic, S, Tyler, D, Woodman, SE, Wright, FC, Zager, JS, Ascierto, PA, Spillane, AJ, van Akkooi, ACJ, Wargo, JA, Blank, CU, Tawbi, HA & Long, GV 2019, 'Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium', The Lancet Oncology, vol. 20, no. 7, pp. e378-e389. https://doi.org/10.1016/S1470-2045(19)30332-8
Amaria, Rodabe N. ; Menzies, Alexander M. ; Burton, Elizabeth M. ; Scolyer, Richard A. ; Tetzlaff, Michael T. ; Antdbacka, Robert ; Ariyan, Charlotte ; Bassett, Roland ; Carter, Brett ; Daud, Adil ; Faries, Mark ; Fecher, Leslie A. ; Flaherty, Keith T. ; Gershenwald, Jeffrey E. ; Hamid, Omid ; Hong, Angela ; Kirkwood, John M. ; Lo, Serigne ; Margolin, Kim ; Messina, Jane ; Postow, Michael A. ; Rizos, Helen ; Ross, Merrick I. ; Rozeman, Elisa A. ; Saw, Robyn P.M. ; Sondak, Vernon ; Sullivan, Ryan J. ; Taube, Janis M. ; Thompson, John F. ; van de Wiel, Bart A. ; Eggermont, Alexander M. ; Davies, Michael A. ; Andrews, Miles C. ; Berry, Donald A. ; Block, Matthew S. ; Boland, Genevieve M. ; Bollin, Kathryn B. ; Carlino, Matteo S. ; Carvajal, Richard D. ; Cohen, Jonathan ; Davar, Diwakar ; Delman, Keith A. ; Dummer, Reinhard ; Farwell, Michael D. ; Fisher, David E. ; Fusi, Alberto ; Glitza, Isabella C. ; de Gruijl, Tanja D. ; Gyorki, David E. ; Hauschild, Axel ; Hieken, Tina J. ; Larkin, James ; Lawson, David H. ; Lebbe, Celeste ; Lee, Jeffrey E. ; Lowe, Michael C. ; Luke, Jason J. ; McArthur, Grant A. ; McDermott, David F. ; McQuade, Jennifer L. ; Mitchell, Tara C. ; Petrella, Teresa M. ; Prieto, Peter A. ; Puzanov, Igor ; Robert, Caroline ; Salama, April K. ; Sandhu, Shaneen ; Schadendorf, Dirk ; Shoushtari, Alexander N. ; Sosman, Jeffrey A. ; Swetter, Susan M. ; Tanabe, Ken K. ; Turajlic, Samra ; Tyler, Douglas ; Woodman, Scott E. ; Wright, Frances C. ; Zager, Jonathan S. ; Ascierto, Paolo A. ; Spillane, Andrew J. ; van Akkooi, Alexander C.J. ; Wargo, Jennifer A. ; Blank, Christian U. ; Tawbi, Hussein A. ; Long, Georgina V. / Neoadjuvant systemic therapy in melanoma : recommendations of the International Neoadjuvant Melanoma Consortium. In: The Lancet Oncology. 2019 ; Vol. 20, No. 7. pp. e378-e389.
@article{add97c93f6994115b0e519978cc51d04,
title = "Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium",
abstract = "Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to treatment, highlighting a crucial need to identify biomarkers and understand mechanisms of response and toxicity. Neoadjuvant therapy for regional metastases might improve operability and clinical outcomes over upfront surgery and adjuvant therapy, and has become an established role for drug development and biomarker discovery in other cancers (including locally advanced breast cancer, head and neck squamous cell carcinomas, gastroesophageal cancer, and anal cancer). Patients with clinically detectable stage III melanoma are ideal candidates for neoadjuvant therapy, because they represent a high-risk patient population with poor outcomes when treated with upfront surgery alone. Neoadjuvant therapy is now an active area of research for melanoma with numerous completed and ongoing trials (since 2014) with disparate designs, endpoints, and analyses under investigation. We have, therefore, established the International Neoadjuvant Melanoma Consortium with experts in medical oncology, surgical oncology, pathology, radiation oncology, radiology, and translational research to develop recommendations for investigating neoadjuvant therapy in melanoma to align future trial designs and correlative analyses. Alignment and consistency of neoadjuvant trials will facilitate optimal data organisation for future regulatory review and strengthen translational research across the melanoma disease continuum.",
author = "Amaria, {Rodabe N.} and Menzies, {Alexander M.} and Burton, {Elizabeth M.} and Scolyer, {Richard A.} and Tetzlaff, {Michael T.} and Robert Antdbacka and Charlotte Ariyan and Roland Bassett and Brett Carter and Adil Daud and Mark Faries and Fecher, {Leslie A.} and Flaherty, {Keith T.} and Gershenwald, {Jeffrey E.} and Omid Hamid and Angela Hong and Kirkwood, {John M.} and Serigne Lo and Kim Margolin and Jane Messina and Postow, {Michael A.} and Helen Rizos and Ross, {Merrick I.} and Rozeman, {Elisa A.} and Saw, {Robyn P.M.} and Vernon Sondak and Sullivan, {Ryan J.} and Taube, {Janis M.} and Thompson, {John F.} and {van de Wiel}, {Bart A.} and Eggermont, {Alexander M.} and Davies, {Michael A.} and Andrews, {Miles C.} and Berry, {Donald A.} and Block, {Matthew S.} and Boland, {Genevieve M.} and Bollin, {Kathryn B.} and Carlino, {Matteo S.} and Carvajal, {Richard D.} and Jonathan Cohen and Diwakar Davar and Delman, {Keith A.} and Reinhard Dummer and Farwell, {Michael D.} and Fisher, {David E.} and Alberto Fusi and Glitza, {Isabella C.} and {de Gruijl}, {Tanja D.} and Gyorki, {David E.} and Axel Hauschild and Hieken, {Tina J.} and James Larkin and Lawson, {David H.} and Celeste Lebbe and Lee, {Jeffrey E.} and Lowe, {Michael C.} and Luke, {Jason J.} and McArthur, {Grant A.} and McDermott, {David F.} and McQuade, {Jennifer L.} and Mitchell, {Tara C.} and Petrella, {Teresa M.} and Prieto, {Peter A.} and Igor Puzanov and Caroline Robert and Salama, {April K.} and Shaneen Sandhu and Dirk Schadendorf and Shoushtari, {Alexander N.} and Sosman, {Jeffrey A.} and Swetter, {Susan M.} and Tanabe, {Ken K.} and Samra Turajlic and Douglas Tyler and Woodman, {Scott E.} and Wright, {Frances C.} and Zager, {Jonathan S.} and Ascierto, {Paolo A.} and Spillane, {Andrew J.} and {van Akkooi}, {Alexander C.J.} and Wargo, {Jennifer A.} and Blank, {Christian U.} and Tawbi, {Hussein A.} and Long, {Georgina V.}",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/S1470-2045(19)30332-8",
language = "English (US)",
volume = "20",
pages = "e378--e389",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "7",

}

TY - JOUR

T1 - Neoadjuvant systemic therapy in melanoma

T2 - recommendations of the International Neoadjuvant Melanoma Consortium

AU - Amaria, Rodabe N.

AU - Menzies, Alexander M.

AU - Burton, Elizabeth M.

AU - Scolyer, Richard A.

AU - Tetzlaff, Michael T.

AU - Antdbacka, Robert

AU - Ariyan, Charlotte

AU - Bassett, Roland

AU - Carter, Brett

AU - Daud, Adil

AU - Faries, Mark

AU - Fecher, Leslie A.

AU - Flaherty, Keith T.

AU - Gershenwald, Jeffrey E.

AU - Hamid, Omid

AU - Hong, Angela

AU - Kirkwood, John M.

AU - Lo, Serigne

AU - Margolin, Kim

AU - Messina, Jane

AU - Postow, Michael A.

AU - Rizos, Helen

AU - Ross, Merrick I.

AU - Rozeman, Elisa A.

AU - Saw, Robyn P.M.

AU - Sondak, Vernon

AU - Sullivan, Ryan J.

AU - Taube, Janis M.

AU - Thompson, John F.

AU - van de Wiel, Bart A.

AU - Eggermont, Alexander M.

AU - Davies, Michael A.

AU - Andrews, Miles C.

AU - Berry, Donald A.

AU - Block, Matthew S.

AU - Boland, Genevieve M.

AU - Bollin, Kathryn B.

AU - Carlino, Matteo S.

AU - Carvajal, Richard D.

AU - Cohen, Jonathan

AU - Davar, Diwakar

AU - Delman, Keith A.

AU - Dummer, Reinhard

AU - Farwell, Michael D.

AU - Fisher, David E.

AU - Fusi, Alberto

AU - Glitza, Isabella C.

AU - de Gruijl, Tanja D.

AU - Gyorki, David E.

AU - Hauschild, Axel

AU - Hieken, Tina J.

AU - Larkin, James

AU - Lawson, David H.

AU - Lebbe, Celeste

AU - Lee, Jeffrey E.

AU - Lowe, Michael C.

AU - Luke, Jason J.

AU - McArthur, Grant A.

AU - McDermott, David F.

AU - McQuade, Jennifer L.

AU - Mitchell, Tara C.

AU - Petrella, Teresa M.

AU - Prieto, Peter A.

AU - Puzanov, Igor

AU - Robert, Caroline

AU - Salama, April K.

AU - Sandhu, Shaneen

AU - Schadendorf, Dirk

AU - Shoushtari, Alexander N.

AU - Sosman, Jeffrey A.

AU - Swetter, Susan M.

AU - Tanabe, Ken K.

AU - Turajlic, Samra

AU - Tyler, Douglas

AU - Woodman, Scott E.

AU - Wright, Frances C.

AU - Zager, Jonathan S.

AU - Ascierto, Paolo A.

AU - Spillane, Andrew J.

AU - van Akkooi, Alexander C.J.

AU - Wargo, Jennifer A.

AU - Blank, Christian U.

AU - Tawbi, Hussein A.

AU - Long, Georgina V.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to treatment, highlighting a crucial need to identify biomarkers and understand mechanisms of response and toxicity. Neoadjuvant therapy for regional metastases might improve operability and clinical outcomes over upfront surgery and adjuvant therapy, and has become an established role for drug development and biomarker discovery in other cancers (including locally advanced breast cancer, head and neck squamous cell carcinomas, gastroesophageal cancer, and anal cancer). Patients with clinically detectable stage III melanoma are ideal candidates for neoadjuvant therapy, because they represent a high-risk patient population with poor outcomes when treated with upfront surgery alone. Neoadjuvant therapy is now an active area of research for melanoma with numerous completed and ongoing trials (since 2014) with disparate designs, endpoints, and analyses under investigation. We have, therefore, established the International Neoadjuvant Melanoma Consortium with experts in medical oncology, surgical oncology, pathology, radiation oncology, radiology, and translational research to develop recommendations for investigating neoadjuvant therapy in melanoma to align future trial designs and correlative analyses. Alignment and consistency of neoadjuvant trials will facilitate optimal data organisation for future regulatory review and strengthen translational research across the melanoma disease continuum.

AB - Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to treatment, highlighting a crucial need to identify biomarkers and understand mechanisms of response and toxicity. Neoadjuvant therapy for regional metastases might improve operability and clinical outcomes over upfront surgery and adjuvant therapy, and has become an established role for drug development and biomarker discovery in other cancers (including locally advanced breast cancer, head and neck squamous cell carcinomas, gastroesophageal cancer, and anal cancer). Patients with clinically detectable stage III melanoma are ideal candidates for neoadjuvant therapy, because they represent a high-risk patient population with poor outcomes when treated with upfront surgery alone. Neoadjuvant therapy is now an active area of research for melanoma with numerous completed and ongoing trials (since 2014) with disparate designs, endpoints, and analyses under investigation. We have, therefore, established the International Neoadjuvant Melanoma Consortium with experts in medical oncology, surgical oncology, pathology, radiation oncology, radiology, and translational research to develop recommendations for investigating neoadjuvant therapy in melanoma to align future trial designs and correlative analyses. Alignment and consistency of neoadjuvant trials will facilitate optimal data organisation for future regulatory review and strengthen translational research across the melanoma disease continuum.

UR - http://www.scopus.com/inward/record.url?scp=85068048029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068048029&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(19)30332-8

DO - 10.1016/S1470-2045(19)30332-8

M3 - Review article

VL - 20

SP - e378-e389

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 7

ER -